{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:28:16Z","timestamp":1758281296381,"version":"3.44.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antibody\u2013drug conjugates (ADCs) represent a promising therapeutic approach in oncology, but managing their toxicities remains challenging. This survey aimed to assess confidence levels in ADC toxicity management among oncology professionals globally.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional survey was conducted using the ONCOassist mobile, a CE-marked oncology application widely used by oncologists globally as support in clinical practice. Confidence in toxicity management was measured on a 5-point scale. Predictor variables included income level, professional role, specialization, and cancer type treated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The survey was offered to 5883 users, and responses were received from 1256 oncology healthcare professionals (HCPs) across various continents and professional roles. Medical oncologists represented the largest group (46%). Most of the HCPs were from high- or upper-middle-income countries (75%) with most nurses (86%) from high-income countries. Respondents from Europe and North America reported higher confidence ratings, while those from Asia, Africa, and Oceania tended to report lower confidence levels (P\u2009&amp;lt;\u2009.001). Respondents from lower-middle-income countries reported lower confidence compared with those from high- and upper-middle-income countries (P\u2009&amp;lt;\u2009.001). Additionally, senior physicians exhibited substantially higher confidence compared to junior physicians and nurse practitioners (P\u2009&amp;lt;\u2009.001, for both). Specialty affected confidence levels, particularly in surgical oncologists who reported the lowest confidence (P\u2009&amp;lt;\u2009.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This global survey reveals significant disparities in confidence levels for managing ADC toxicities across regions, professional roles, and specializations. These findings may suggest the need for targeted educational interventions and support systems to enhance competences in managing ADC-related toxicities, ultimately improving the global standard of care for patients receiving ADCs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf232","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:54:58Z","timestamp":1753714498000},"source":"Crossref","is-referenced-by-count":0,"title":["Global variations in oncology professionals\u2019 confidence levels for managing antibody\u2013drug conjugate toxicities: a cross-continental survey"],"prefix":"10.1093","volume":"30","author":[{"given":"Marina","family":"Campione","sequence":"first","affiliation":[{"name":"Faculty of Economics and Law of University of Enna Kore , Enna 94100,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7877-8988","authenticated-orcid":false,"given":"Michele","family":"Maffezzoli","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth PO6 3LY,","place":["United Kingdom"]},{"name":"Medical Oncology Unit, University Hospital of Parma , Parma,","place":["Italy"]},{"name":"Department of Medicine and Surgery, University of Parma , Parma,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruni","family":"Ghose","sequence":"additional","affiliation":[{"name":"Barts Cancer Centre, St Bartholomew\u2019s Hospital, Barts Health NHS Trust , London,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Maniam","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth PO6 3LY,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ria","family":"Nagpal","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth PO6 3LY,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Centre for Cancer, Newcastle University , Newcastle upon Tyne,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma , Parma,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renita","family":"George","sequence":"additional","affiliation":[{"name":"ONCOassist ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Bambury","sequence":"additional","affiliation":[{"name":"ONCOassist ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bambury","sequence":"additional","affiliation":[{"name":"ONCOassist ,","place":["Ireland"]},{"name":"CUH\/UCC Cancer Centre, Cork University Hospital , Cork,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoin","family":"O\u2019Carroll","sequence":"additional","affiliation":[{"name":"ONCOassist ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth PO6 3LY,","place":["United Kingdom"]},{"name":"Faculty of Science & Health, School of Pharmacy & Biomedical Sciences, University of Portsmouth , Portsmouth PO1 2UP,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2025091815425044300_oyaf232-B1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11912-024-01524-7","article-title":"Antibody drug conjugates in urological cancers: a review of the current landscape","volume":"26","author":"Ghose","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"2025091815425044300_oyaf232-B2","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"2025091815425044300_oyaf232-B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025091815425044300_oyaf232-B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136969","article-title":"Antibody-drug conjugates-evolution and perspectives","volume":"25","author":"Chis","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025091815425044300_oyaf232-B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"2025091815425044300_oyaf232-B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025091815425044300_oyaf232-B7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00262-012-1369-3","article-title":"Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake","volume":"62","author":"Gorovits","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2025091815425044300_oyaf232-B8","doi-asserted-by":"publisher","first-page":"e007572","DOI":"10.1136\/jitc-2023-007572","article-title":"SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models","volume":"11","author":"Gray","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025091815425044300_oyaf232-B9","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1158\/1538-7445.AM2020-5581","article-title":"Abstract 5581: Enfortumab vedotin, an anti-nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers","volume":"80","author":"Liu","year":"2020","journal-title":"Cancer Res"},{"key":"2025091815425044300_oyaf232-B10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025091815425044300_oyaf232-B11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br J Cancer"},{"key":"2025091815425044300_oyaf232-B12","doi-asserted-by":"publisher","first-page":"e13555","DOI":"10.2196\/13555","article-title":"Clinicians\u2019 role in the adoption of an oncology decision support app in Europe and its implications for organizational practices: qualitative case study","volume":"7","author":"Jacob","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"2025091815425044300_oyaf232-B13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/B:QURE.0000018499.64574.1f","article-title":"Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?","volume":"13","author":"de Boer","year":"2004","journal-title":"Qual Life Res"},{"key":"2025091815425044300_oyaf232-B14","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1054\/bjoc.2001.1785","article-title":"Clinical relevance of single item quality of life indicators in cancer clinical trials","volume":"84","author":"Bernhard","year":"2001","journal-title":"Br J Cancer"},{"key":"2025091815425044300_oyaf232-B15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00520-024-08775-x","article-title":"Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer","volume":"32","author":"Gharzai","year":"2024","journal-title":"Support Care Cancer"},{"key":"2025091815425044300_oyaf232-B16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10880-015-9436-5","article-title":"Are single-item global ratings useful for assessing health status?","volume":"22","author":"Macias","year":"2015","journal-title":"J Clin Psychol Med Settings"},{"key":"2025091815425044300_oyaf232-B17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2466\/pr0.1991.69.1.127","article-title":"Single-item vs multiple-item measures of health-related quality of life","volume":"69","author":"Cunny","year":"1991","journal-title":"Psychol Rep"},{"key":"2025091815425044300_oyaf232-B18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1200\/JCO.2011.39.6184","article-title":"Communication skills training for oncology professionals","volume":"30","author":"Kissane","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025091815425044300_oyaf232-B19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.2015.65.8427","article-title":"Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"34","author":"Dizon","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025091815425044300_oyaf232-B20","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1093\/oncolo\/oyac133","article-title":"International survey on frailty assessment in patients with cancer","volume":"27","author":"Banna","year":"2022","journal-title":"Oncologist"},{"key":"2025091815425044300_oyaf232-B21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s13187-019-01675-3","article-title":"A translational approach to cancer research, education and training","volume":"36","author":"Ezelle","year":"2021","journal-title":"J Cancer Educ"},{"key":"2025091815425044300_oyaf232-B22","doi-asserted-by":"publisher","first-page":"104241","DOI":"10.1016\/j.drudis.2024.104241","article-title":"Antibody\u2013drug conjugates: prospects for the next generation","volume":"29","author":"Grairi","year":"2024","journal-title":"Drug Discov Today"},{"key":"2025091815425044300_oyaf232-B23","doi-asserted-by":"publisher","first-page":"104527","DOI":"10.1016\/j.critrevonc.2024.104527","article-title":"Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: a systematic review and meta-analysis","volume":"204","author":"Belloni","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025091815425044300_oyaf232-B24","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.esmogo.2025.100154","article-title":"Expanding the potential of antibody\u2013drug conjugates in gastrointestinal malignancies: beyond HER2 targets","volume":"8","author":"Ntellas","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"2025091815425044300_oyaf232-B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2025091815425044300_oyaf232-B26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ctrv.2010.04.005","article-title":"Anticancer oral therapy: emerging related issues","volume":"36","author":"Banna","year":"2010","journal-title":"Cancer Treat Rev"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf232\/63865214\/oyaf232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf232\/63865214\/oyaf232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf232\/63865214\/oyaf232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:43:00Z","timestamp":1758224580000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf232\/8215414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf232","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,28]]},"article-number":"oyaf232"}}